The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma

Time: 11:30 am
day: Day One


  • ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients
  • To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach via the integration of in vitro coculture systems and in vivo preclinical models with human patient data from our clinical trial
  • We describe a novel role for ASTX660 as an immunomodulatory molecule, capable acting on both the innate and adaptive immune system, which could be exploited to remodel the tumor immune microenvironment